New antibody combo takes on Hard-to-Treat cancers

NCT ID NCT06451497

Recruiting now Disease control Sponsor: Zumutor Biologics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combination can shrink tumors. About 100 participants who have exhausted standard treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZM008 (an antibody) given alone and then combined with toripalimab (another antibody)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. It may not shrink tumors, and side effects are unknown. Only a small number of people will be tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colorectal cancer colorectal neoplasm diffuse large B-cell lymphoma head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian serous adenocarcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma prostate cancer renal cell carcinoma Squamous Cell Carcinoma of Head and Neck transitional cell carcinoma triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER COLORECTAL CANCER DIFFUSE LARGE B-CELL LYMPHOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA HIGH GRADE OVARIAN SEROUS ADENOCARCINOMA NON-SMALL CELL LUNG CANCER PANCREAS ADENOCARCINOMA PROSTATE CANCER RENAL CELL CANCER METASTATIC TRIPLE NEGATIVE BREAST CANCER UROTHELIAL CARCINOMA

Contacts and locations

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
NEXT Oncology
RECRUITING

Austin, TX 78758, Texas, 78758, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.